Ticagrelor with or without Aspirin in High-Risk Patients after PCI.

R, Mehran; U, Baber; SK, Sharma; DJ, Cohen; DJ, Angiolillo; C, Briguori; JY, Cha; T, Collier; G, Dangas; D, Dudek; V, Džavík; J, Escaned; R, Gil; P, Gurbel; CW, Hamm; T, Henry; K, Huber; A, Kastrati; U, Kaul; R, Kornowski; M, Krucoff; V, Kunadian; SO, Marx; SR, Mehta; D, Moliterno; EM, Ohman; K, Oldroyd; G, Sardella; S, Sartori; R, Shlofmitz; PG, Steg; G, Weisz; B, Witzenbichler; YL, Han; S, Pocock; CM, Gibson

doi:10.1056/nejmoa1908419

Public

Ticagrelor with or without Aspirin in High-Risk Patients after PCI.

Shared by NobleBlocks on Sep 26, 2019 • 12:00 AM UTC

Authors:

Mehran R

Baber U

Sharma SK

Abstract

Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI).Methods In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagre...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!